Research
Hormonal
Utilizing lipid panels (specifically triglycerides and LDL-C levels) serves as a valid clinical indicator for assessing insulin resistance.
Monitor lipid panels, particularly triglycerides and LDL-C, as they are strong indicators of insulin resistance. High HDL-C is associated with increased insulin sensitivity.
ModerateSupportsMEDIUM confidence
The present approach recognizes that dyslipidemia, characterized by lipid level deviations, frequently coexists with insulin resistance. Insulin resistance is commonly associated with increased triglyceride and low-density lipoprotein cholesterol (LDL-C) levels.
Why this rating
Bibliometric analysis of RCTs; confirms the association but does not provide new primary data.
Source
Mapping the landscape of research on insulin resistance: a visualization analysis of randomized clinical trials
Sa’ed H. Zyoud · Journal of Health Population and Nutrition · 2024
DOI 10.1186/s41043-024-00497-4
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Randomized clinical trials demonstrate that dietary interventions (specifically low-carbohydrate or high-fiber diets) and physical activity significantly improve insulin sensitivity in obese individuals.Moderate
- Insulin resistance in patients with polycystic ovary syndrome (PCOS) is a distinct and significant research hotspot, with metformin and glucose tolerance being key intervention and outcome measures.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →